CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Parkinson Disease
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: A Phase III Randomised Controlled Trial of Rivastigmine versus PlaceboMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Double blindPrimary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04226248
- Collaborators
- Royal United Hospitals Bath NHS Foundation Trust
- Investigators
- Principal Investigator: Emily Henderson, PhD University of Bristol